Tracy Song appointed as Chief Financial Officer (CFO) of ImmuneOnco

Shanghai, China, July 26, 2021 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that Ms.Tracy(Ziyi) Song has been appointed as the Chief Financial Officer (CFO) of the company, reporting to Dr.......

2021-07-27

New Milestone: The Bi-specific CD47XHER2 fusion protein, IMM2902 approved for clinical trial by National Medical Products Administration (NMPA)

June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2......

2021-07-01

ImmuneOnco Held 2021 Shareholders’ Conference

June 16, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") 2021 annual meeting of shareholders was successfully held at "47" Building, Lane 908, Ziping Road. The founder and chairman of Imm......

2021-06-17

ImmuneOnco to Present at 2021 BIO Digital

Shanghai, China, June 10, 2021 – ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced today that it was selected to present at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled at June 10-11 & 14-18, 2021. ......

2021-06-11

Ground Breaking Ceremony of New building for ImmuneOnco R&D Centre

On March31, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the building for R&D center, located in Lane 100, Banxia Road, Zhoupu, Shanghai (Cell Industrial Park), was officially commenced. The new R&......

2021-04-22